Litcius/Paper detail

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial

Yiming Mu, Xiao-lei Bao, Freddy G. Eliaschewitz, Morten Hansen, Bom Taeck Kim, Anna Koroleva, Ronald C.W., Tao Yang, Ning Zu, Ming Liu

2024The Lancet Diabetes & Endocrinology114 citationsDOI

Topics & Concepts

MedicineOverweightSemaglutideWeight managementRandomized controlled trialObesityPopulationWeight lossPhysical therapyDouble blindGerontologyType 2 diabetesTraditional medicineDiabetes mellitusAlternative medicineInternal medicineEnvironmental healthPlaceboEndocrinologyLiraglutidePathologyDiabetes Treatment and ManagementBariatric Surgery and OutcomesMetabolism, Diabetes, and Cancer
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial | Litcius